The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Breast cancer has grown to be the second leading cause of cancer-related deaths in
women. Only a few treatment options are available for breast cancer due to the widespread …

Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives
growth arrest and apoptosis, whereas chronic exposure to low concentrations provides …

Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy
compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is …

Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer
deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic …

Intratumoral heterogeneity is a major ongoing challenge in the effective therapeutic targeting
of cancer. Accumulating evidence suggests that a fraction of cells within a tumor termed …

Simple Summary The cancer cells in solid tumors are embedded in a complex connective
tissue matrix composed of various other cell types, ie, mesenchymal stroma/stem-like cells …

Epithelial–mesenchymal plasticity (EMP) plays critical roles during embryonic development,
wound repair, fibrosis, inflammation and cancer. During cancer progression, EMP results in …

Cancer stem cells (CSCs) are a minority subset of cancer cells that can drive tumor initiation,
promote tumor progression, and induce drug resistance. CSCs are difficult to eliminate by …

Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests
negative for estrogen receptors (ER), progesterone receptors (PR), and excess human …